Dear Shareholders and readers
This year has been transformative for Diamyd Medical. In December 2019, and later published in August 2020 in Diabetologia, we could show with data from more than 500 patients from three trials, that the individual’s genes, more specifically the HLA genes of the individual, influences the treatment effect of the diabetes vaccine Diamyd®. To confirm this finding in a prospective trial, the same analysis was specified as a part of the main analysis in the statistical analysis protocol and included...